#Sweden #Stockholm #EQT Life Sciences #Alzheimer's therapy #Exciva

EQT Life Sciences Co-Leads €51 Million Series B Funding for Exciva

EQT Life Sciences has announced a significant investment in Exciva, a clinical-stage biopharmaceutical company focused on innovative treatments for behavioral symptoms related to Alzheimer's disease (AD). This funding round, which amounts to €51 million in Series B financing, marks a pivotal moment in Exciva's mission to advance its lead therapeutic candidate, Deraphan, into the promising Phase 2 clinical trial stage.

Commitment to Addressing Unmet Needs

The decision to co-lead this investment came from EQT Life Sciences' LSP Dementia Fund, alongside other notable investors, including Gimv, Fountain Healthcare Partners, and LifeArc. This collaborative effort underscores a shared dedication to tackling the urgent and unmet needs in Alzheimer's care, particularly given that neuropsychiatric symptoms such as agitation affect a staggering 90% of patients with severe AD. These symptoms not only diminish the quality of life for patients but also increase the burden on caregivers and healthcare systems.

As the global population ages rapidly, there has been a noticeable lag in innovative therapeutic solutions for Alzheimer's. The Series B funding will specifically support clinical trials across Europe, the United States, and Canada to evaluate Deraphan for its efficacy in alleviating agitation—one of the more distressing behavioral symptoms associated with Alzheimer's.

A Scientific Foundation

Deraphan is built on a robust scientific background, combining two clinically validated compounds along with a new chemical entity. The initial Phase 1 trials have already demonstrated promising safety and tolerability, paving the way for further studies that may lead to differentiated efficacy and safety profiles. Unlike many current treatment options, which are often encumbered by significant side effects and black box warnings, Deraphan shows the potential to offer a viable alternative for patients.

François Conquet, the CEO of Exciva, expressed his enthusiasm regarding the funding, stating, "We are delighted that we could attract funding from both new and existing investors, supporting our belief that our compound is promising. If the results of the Phase 2 trials are positive, it would be a significant milestone in symptomatic treatment options for patients with AD." This statement captures the optimism surrounding the trial and the potential impact of their findings.

EQT Life Sciences’ Perspective

Philip Scheltens, MD, PhD, and a partner at EQT Life Sciences, echoed similar sentiments, emphasizing the groundbreaking potential of Exciva's approach in a therapeutic landscape that requires urgent innovation. He noted, "This investment illustrates the potential of Exciva to bring exciting innovation to a therapeutic area where Alzheimer's patients have limited or no treatment options. We are delighted to co-lead this financing to help realize Exciva's potential, which stands out for both the quality of its science and the expertise of its team. We look forward to bringing this innovation to patients." Such insights highlight the strategic importance of this investment in reshaping care paradigms in Alzheimer's care.

Future Leadership and Board Involvement

With the completion of this funding round, EQT Life Sciences will have representation in Exciva's Board of Directors, with Philip Scheltens assuming the role of Director and Juliette Lee serving as an Observer. This involvement indicates a commitment to guiding Exciva through its pivotal development stages and underscores the partnership's potential for impactful achievements in addressing Alzheimer’s-related challenges.

In conclusion, EQT Life Sciences' co-lead in Exciva’s €51 Million Series B funding marks a significant advancement toward innovative Alzheimer's treatment solutions, particularly in mitigating agitation symptoms that detrimentally affect patients and caregivers alike. As clinical trials progress, the global community watches keenly, hopeful for breakthroughs that can enhance the standard of care in Alzheimer's treatment.